Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53

Faina Vikhanskaya, Luana Clerico, Monica Valenti, Maria S. Stanzione, Massimo Broggini, Silvio Parodi, Patrizia Russo

Research output: Contribution to journalArticle

Abstract

A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity and apoptosis. Resistance is not related to the amount of cross-links. Topoisomerase-II (topII) protein levels were similar in both cell lines, with lower cleavage activity in A2780-DX3 cells. The parental and the doxorubicin- resistant cells expressed the same level of c-erb2, which could be implicated in CDDP resistance. bcl2 was almost undetectable in both cell lines. At the same time, we found strong induction of p53, waf-I and bax protein levels after CDDP treatment in the A2780, but not in the A2780-DX3, cell line. Treatment of both cell lines with mitomycin C (MMC), which acts with a mechanism different from CDDP, caused equal accumulation of p53 and induction of bax. We found that A2780-DX3 cells exhibit altered cellular localization of p53 protein in comparison with A2780. A significant proportion of p53 in A2780-DX3 cells was found in the cytoplasmic compartment, and CDDP treatment induced a functional p53 protein in the nucleus of A2780 much more strongly than in A2780-DX3, which coincides with an increase of transcriptional activity of p53 in treated A2780 cells. We propose that the cross-resistance to CDDP in the A2780-DX3 cell line may be due to inactivation of a CDDP- dependent p53-accumulation pathway.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalInternational Journal of Cancer
Volume72
Issue number1
DOIs
Publication statusPublished - Jul 3 1997

Fingerprint

Doxorubicin
Cisplatin
Carcinoma
Cell Line
bcl-2-Associated X Protein
Type II DNA Topoisomerase
Proteins
Multiple Drug Resistance
Mitomycin
Ovarian Neoplasms
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin : Possible role of p53. / Vikhanskaya, Faina; Clerico, Luana; Valenti, Monica; Stanzione, Maria S.; Broggini, Massimo; Parodi, Silvio; Russo, Patrizia.

In: International Journal of Cancer, Vol. 72, No. 1, 03.07.1997, p. 155-159.

Research output: Contribution to journalArticle

Vikhanskaya, Faina ; Clerico, Luana ; Valenti, Monica ; Stanzione, Maria S. ; Broggini, Massimo ; Parodi, Silvio ; Russo, Patrizia. / Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin : Possible role of p53. In: International Journal of Cancer. 1997 ; Vol. 72, No. 1. pp. 155-159.
@article{3114d7db0a1d4d09aaebedf9383bd615,
title = "Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53",
abstract = "A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity and apoptosis. Resistance is not related to the amount of cross-links. Topoisomerase-II (topII) protein levels were similar in both cell lines, with lower cleavage activity in A2780-DX3 cells. The parental and the doxorubicin- resistant cells expressed the same level of c-erb2, which could be implicated in CDDP resistance. bcl2 was almost undetectable in both cell lines. At the same time, we found strong induction of p53, waf-I and bax protein levels after CDDP treatment in the A2780, but not in the A2780-DX3, cell line. Treatment of both cell lines with mitomycin C (MMC), which acts with a mechanism different from CDDP, caused equal accumulation of p53 and induction of bax. We found that A2780-DX3 cells exhibit altered cellular localization of p53 protein in comparison with A2780. A significant proportion of p53 in A2780-DX3 cells was found in the cytoplasmic compartment, and CDDP treatment induced a functional p53 protein in the nucleus of A2780 much more strongly than in A2780-DX3, which coincides with an increase of transcriptional activity of p53 in treated A2780 cells. We propose that the cross-resistance to CDDP in the A2780-DX3 cell line may be due to inactivation of a CDDP- dependent p53-accumulation pathway.",
author = "Faina Vikhanskaya and Luana Clerico and Monica Valenti and Stanzione, {Maria S.} and Massimo Broggini and Silvio Parodi and Patrizia Russo",
year = "1997",
month = "7",
day = "3",
doi = "10.1002/(SICI)1097-0215(19970703)72:1<155::AID-IJC22>3.0.CO;2-H",
language = "English",
volume = "72",
pages = "155--159",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin

T2 - Possible role of p53

AU - Vikhanskaya, Faina

AU - Clerico, Luana

AU - Valenti, Monica

AU - Stanzione, Maria S.

AU - Broggini, Massimo

AU - Parodi, Silvio

AU - Russo, Patrizia

PY - 1997/7/3

Y1 - 1997/7/3

N2 - A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity and apoptosis. Resistance is not related to the amount of cross-links. Topoisomerase-II (topII) protein levels were similar in both cell lines, with lower cleavage activity in A2780-DX3 cells. The parental and the doxorubicin- resistant cells expressed the same level of c-erb2, which could be implicated in CDDP resistance. bcl2 was almost undetectable in both cell lines. At the same time, we found strong induction of p53, waf-I and bax protein levels after CDDP treatment in the A2780, but not in the A2780-DX3, cell line. Treatment of both cell lines with mitomycin C (MMC), which acts with a mechanism different from CDDP, caused equal accumulation of p53 and induction of bax. We found that A2780-DX3 cells exhibit altered cellular localization of p53 protein in comparison with A2780. A significant proportion of p53 in A2780-DX3 cells was found in the cytoplasmic compartment, and CDDP treatment induced a functional p53 protein in the nucleus of A2780 much more strongly than in A2780-DX3, which coincides with an increase of transcriptional activity of p53 in treated A2780 cells. We propose that the cross-resistance to CDDP in the A2780-DX3 cell line may be due to inactivation of a CDDP- dependent p53-accumulation pathway.

AB - A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity and apoptosis. Resistance is not related to the amount of cross-links. Topoisomerase-II (topII) protein levels were similar in both cell lines, with lower cleavage activity in A2780-DX3 cells. The parental and the doxorubicin- resistant cells expressed the same level of c-erb2, which could be implicated in CDDP resistance. bcl2 was almost undetectable in both cell lines. At the same time, we found strong induction of p53, waf-I and bax protein levels after CDDP treatment in the A2780, but not in the A2780-DX3, cell line. Treatment of both cell lines with mitomycin C (MMC), which acts with a mechanism different from CDDP, caused equal accumulation of p53 and induction of bax. We found that A2780-DX3 cells exhibit altered cellular localization of p53 protein in comparison with A2780. A significant proportion of p53 in A2780-DX3 cells was found in the cytoplasmic compartment, and CDDP treatment induced a functional p53 protein in the nucleus of A2780 much more strongly than in A2780-DX3, which coincides with an increase of transcriptional activity of p53 in treated A2780 cells. We propose that the cross-resistance to CDDP in the A2780-DX3 cell line may be due to inactivation of a CDDP- dependent p53-accumulation pathway.

UR - http://www.scopus.com/inward/record.url?scp=0030745894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030745894&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19970703)72:1<155::AID-IJC22>3.0.CO;2-H

DO - 10.1002/(SICI)1097-0215(19970703)72:1<155::AID-IJC22>3.0.CO;2-H

M3 - Article

C2 - 9212237

AN - SCOPUS:0030745894

VL - 72

SP - 155

EP - 159

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -